Logo

JACS

Jackson Acquisition Company II

JACS

Jackson Acquisition Company II • NYSE
$10.41 ▼ -0.19% (-0.02)
Market Cap $308.03 M
52w High $10.47
52w Low $9.94
Dividend Yield 0%
P/E 0
Volume 247
Outstanding Shares 29.59M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $129.619K ▲ $2.346M ▲ 0% $0.08 ▲ $2.346M ▲
Q2-2025 $0 $129.037K ▼ $2.318M ▲ 0% $0.078 ▲ $-129.037K ▼
Q1-2025 $0 $206.321K ▲ $2.227M ▲ 0% $0.075 ▲ $2.227M ▲
Q4-2024 $0 $177.396K ▲ $381.082K ▲ 0% $0.04 ▲ $-177.396K ▼
Q3-2024 $0 $49.568K $-49.568K 0% $-0.002 $-49.568K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $585.116K ▼ $240.926M ▲ $240.602M ▲ $324.886K ▼
Q2-2025 $721.661K ▼ $238.635M ▲ $441.173K ▲ $238.194M ▲
Q1-2025 $755.968K ▼ $236.281M ▲ $405.164K ▲ $235.876M ▲
Q4-2024 $949.366K ▲ $234.006M ▲ $357.54K ▲ $233.648M ▲
Q3-2024 $0 $193.8K $218.368K $-24.568K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $2.346M ▲ $-136.545K ▼ $0 $0 $-136.545K ▼ $-136.545K ▼
Q2-2025 $2.318M ▲ $-34.307K ▲ $0 $0 $-34.307K ▲ $-34.307K ▲
Q1-2025 $2.227M ▲ $-193.398K ▲ $0 ▲ $0 ▼ $-193.398K ▼ $-193.398K ▲
Q4-2024 $381.082K $-302.833K $-232.3M $233.552M $949.366K $-302.833K

Five-Year Company Overview

Income Statement

Income Statement JACS currently has no real operating business, so its income statement is basically a placeholder. There is no meaningful revenue, no core operating profit, and any small earnings are likely tied to interest on cash rather than an underlying company. This is typical for a newly formed SPAC: the financials do not yet tell a story about business performance, only about a pool of capital waiting to be deployed through a merger.

Balance Sheet

Balance Sheet The balance sheet is very simple and reflects the SPAC structure. Assets are almost entirely cash or cash-like holdings raised in the IPO, with equity roughly matching those assets and no visible debt. In practical terms, this means JACS is essentially a cash shell with a clean, low‑risk balance sheet for now. The key question is not today’s financial strength, but how that cash will be used and what kind of company will eventually sit on this balance sheet after a merger.

Cash Flow

Cash Flow Cash flows are minimal and not yet meaningful. There is no operating cash flow from a real business, no investment in long‑term assets, and only modest, routine SPAC-related costs. Until JACS completes a deal, cash flow statements mainly show the preservation of IPO proceeds rather than any pattern of business health, growth, or efficiency. The crucial shift will occur only once a merger closes and an operating company’s cash flows replace today’s static profile.

Competitive Edge

Competitive Edge As a blank‑check company, JACS does not compete through products, customers, or technology. Its current “edge,” if any, lies in its management team, sector focus, and reputation in healthcare services and health technology. The team’s industry experience may help them source and evaluate better targets than a generic SPAC. However, JACS also operates in a crowded field of SPACs and traditional IPO options, so its ultimate competitive position will depend entirely on the quality, uniqueness, and scale of the company it merges with.

Innovation and R&D

Innovation and R&D JACS itself does not conduct research, build technology, or own innovative products. Its role is to find and merge with a healthcare or health‑tech company that already has these strengths. The real innovation story—patents, software platforms, data tools, or specialized services—will belong to the eventual target. Management’s stated aim is to focus on companies using technology to improve care, efficiency, and data use in healthcare, so the R&D and innovation profile of this future partner will be central to JACS’ long‑term identity.

Summary

JACS is a very early‑stage, pure SPAC: financially simple, operationally inactive, and entirely defined by what it might acquire in the future. Today’s accounts show a cash-rich, debt‑free shell with no real revenue, profit, or cash‑flow pattern. The main strengths are a focused mandate in a large, evolving healthcare market and a leadership team with sector experience. The main risks are typical SPAC uncertainties: the ability to find a strong target at a reasonable valuation, the time limit to get a deal done, regulatory and shareholder approvals, and potential dilution once a transaction is structured. Until a specific merger partner is announced, analysis is mostly about management credibility and strategy rather than business performance, because the true economics and competitive moat will only be visible after the “future” operating company is revealed.